Beijing- China’s vaccine specialist CanSino Biologics Inc has won a patent approval from Beijing for its COVID-19 vaccine candidate Ad5-nCOV, state media reported, citing documents from the country’s intellectual property regulator.
It is the first COVID-19 vaccine patent granted by China, state-owned newspaper People’s Daily reported on Sunday.
The paper cited documents published by China’s National Intellectual Property Administration saying that the patent was issued on August 11.
Saudi Arabia said this month it plans to begin Phase III clinical trials for the CanSino vaccine. CanSino has said it is also in talks with Russia, Brazil and Chile to launch Phase III trials in those countries.
CanSino’s Hong Kong shares rose around 14 per cent in Monday’s morning session. Its Shanghai shares rose by 6.6 per cent as of midday.
Be Part of Quality Journalism
Quality journalism takes a lot of time, money and hard work to produce and despite all the hardships we still do it. Our reporters and editors are working overtime in Kashmir and beyond to cover what you care about, break big stories, and expose injustices that can change lives. Today more people are reading Kashmir Observer than ever, but only a handful are paying while advertising revenues are falling fast.